Testicular Neoplasm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major testicular neoplasm markets reached a value of US$ 480.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 800.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.76% during 2024-2034.
The testicular neoplasm market has been comprehensively analyzed in IMARC's new report titled "Testicular Neoplasm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Testicular neoplasm refers to the development of tumors or abnormal growth in the testicles, which are the male reproductive organs that produce testosterone and sperm. This condition is further classified into two main types: seminomas and non-seminomas. Seminomas tend to grow at a slower pace and mostly affect men in their 40s and 50s, while non-seminomas are more aggressive and have a peak incidence in the third decade of life. Individuals suffering from the illness may experience a lump or swelling in either testicle, a dull ache in the lower belly or groin, sudden swelling with a feeling of heaviness in the scrotum, unexplained weight loss, back pain, etc. The diagnosis of testicular neoplasm requires a combination of clinical features, medical history, blood workups, and a complete physical examination. Various other diagnostic procedures used to confirm a prognosis include computerized tomography scans, X-rays of the affected site, magnetic resonance imaging, etc. The healthcare provider may also conduct a biopsy to evaluate the characteristic features of abnormal cells in patients.
The rising cases of genetic conditions and congenital abnormalities that cause cells to multiply faster than usual, thereby leading to the formation of a lump or tumor, are primarily driving the testicular neoplasm market. In addition to this, the increasing incidences of several associated risk factors, including undescended testicles, family history, human immunodeficiency virus infection, etc., are also bolstering the market growth. Moreover, the widespread adoption of external-beam radiation therapy, which utilizes high-energy rays to destroy cancerous cells or slow their spread, is further creating a positive outlook for the market. Apart from this, the escalating demand for immune checkpoint inhibitors, such as pembrolizumab and nivolumab, for preventing disease progression and increasing the probability of long-term survival in patients is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of combination approaches, including high-dose chemotherapy followed by stem cell transplantation, owing to their numerous advantages, like enhanced treatment intensity, improved remission rates, reconstitution of bone marrow function, etc., is expected to drive the testicular neoplasm market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the testicular neoplasm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for testicular neoplasm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the testicular neoplasm market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the testicular neoplasm market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the testicular neoplasm market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current testicular neoplasm marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the testicular neoplasm market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the testicular neoplasm market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the testicular neoplasm market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of testicular neoplasm across the seven major markets?
What is the number of prevalent cases (2018-2034) of testicular neoplasm by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of testicular neoplasm by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with testicular neoplasm across the seven major markets?
What is the size of the testicular neoplasm patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of testicular neoplasm?
What will be the growth rate of patients across the seven major markets?
Testicular Neoplasm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for testicular neoplasm drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the testicular neoplasm market?
What are the key regulatory events related to the testicular neoplasm market?
What is the structure of clinical trial landscape by status related to the testicular neoplasm market?
What is the structure of clinical trial landscape by phase related to the testicular neoplasm market?
What is the structure of clinical trial landscape by route of administration related to the testicular neoplasm market?
The testicular neoplasm market has been comprehensively analyzed in IMARC's new report titled "Testicular Neoplasm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Testicular neoplasm refers to the development of tumors or abnormal growth in the testicles, which are the male reproductive organs that produce testosterone and sperm. This condition is further classified into two main types: seminomas and non-seminomas. Seminomas tend to grow at a slower pace and mostly affect men in their 40s and 50s, while non-seminomas are more aggressive and have a peak incidence in the third decade of life. Individuals suffering from the illness may experience a lump or swelling in either testicle, a dull ache in the lower belly or groin, sudden swelling with a feeling of heaviness in the scrotum, unexplained weight loss, back pain, etc. The diagnosis of testicular neoplasm requires a combination of clinical features, medical history, blood workups, and a complete physical examination. Various other diagnostic procedures used to confirm a prognosis include computerized tomography scans, X-rays of the affected site, magnetic resonance imaging, etc. The healthcare provider may also conduct a biopsy to evaluate the characteristic features of abnormal cells in patients.
The rising cases of genetic conditions and congenital abnormalities that cause cells to multiply faster than usual, thereby leading to the formation of a lump or tumor, are primarily driving the testicular neoplasm market. In addition to this, the increasing incidences of several associated risk factors, including undescended testicles, family history, human immunodeficiency virus infection, etc., are also bolstering the market growth. Moreover, the widespread adoption of external-beam radiation therapy, which utilizes high-energy rays to destroy cancerous cells or slow their spread, is further creating a positive outlook for the market. Apart from this, the escalating demand for immune checkpoint inhibitors, such as pembrolizumab and nivolumab, for preventing disease progression and increasing the probability of long-term survival in patients is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of combination approaches, including high-dose chemotherapy followed by stem cell transplantation, owing to their numerous advantages, like enhanced treatment intensity, improved remission rates, reconstitution of bone marrow function, etc., is expected to drive the testicular neoplasm market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the testicular neoplasm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for testicular neoplasm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the testicular neoplasm market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the testicular neoplasm market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the testicular neoplasm market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current testicular neoplasm marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the testicular neoplasm market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the testicular neoplasm market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the testicular neoplasm market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of testicular neoplasm across the seven major markets?
What is the number of prevalent cases (2018-2034) of testicular neoplasm by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of testicular neoplasm by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with testicular neoplasm across the seven major markets?
What is the size of the testicular neoplasm patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of testicular neoplasm?
What will be the growth rate of patients across the seven major markets?
Testicular Neoplasm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for testicular neoplasm drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the testicular neoplasm market?
What are the key regulatory events related to the testicular neoplasm market?
What is the structure of clinical trial landscape by status related to the testicular neoplasm market?
What is the structure of clinical trial landscape by phase related to the testicular neoplasm market?
What is the structure of clinical trial landscape by route of administration related to the testicular neoplasm market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TESTICULAR NEOPLASM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TESTICULAR NEOPLASM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TESTICULAR NEOPLASM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 TESTICULAR NEOPLASM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TESTICULAR NEOPLASM - UNMET NEEDS
10 TESTICULAR NEOPLASM - KEY ENDPOINTS OF TREATMENT
11 TESTICULAR NEOPLASM - MARKETED PRODUCTS
11.1 List of Testicular Neoplasm Marketed Drugs Across the Top 7 Markets
11.1.1 Etopophos (Etoposide phosphate) - Bristol-Myers Squibb
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TESTICULAR NEOPLASM - PIPELINE DRUGS
12.1 List of Testicular Neoplasm Pipeline Drugs Across the Top 7 Markets
12.1.1 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Oxaliplatin - Dr Reddy's Laboratories/Pfizer/Sanofi/Yakult Honsha
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TESTICULAR NEOPLASM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TESTICULAR NEOPLASM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TESTICULAR NEOPLASM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Testicular Neoplasm - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Testicular Neoplasm - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Testicular Neoplasm - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Testicular Neoplasm - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Testicular Neoplasm - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Testicular Neoplasm - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Testicular Neoplasm - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Testicular Neoplasm - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Testicular Neoplasm - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Testicular Neoplasm - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Testicular Neoplasm - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Testicular Neoplasm - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Testicular Neoplasm - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Testicular Neoplasm - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Testicular Neoplasm - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Testicular Neoplasm - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Testicular Neoplasm - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Testicular Neoplasm - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Testicular Neoplasm - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Testicular Neoplasm - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Testicular Neoplasm - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Testicular Neoplasm - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Testicular Neoplasm - Access and Reimbursement Overview
16 TESTICULAR NEOPLASM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TESTICULAR NEOPLASM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TESTICULAR NEOPLASM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TESTICULAR NEOPLASM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TESTICULAR NEOPLASM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TESTICULAR NEOPLASM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 TESTICULAR NEOPLASM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TESTICULAR NEOPLASM - UNMET NEEDS
10 TESTICULAR NEOPLASM - KEY ENDPOINTS OF TREATMENT
11 TESTICULAR NEOPLASM - MARKETED PRODUCTS
11.1 List of Testicular Neoplasm Marketed Drugs Across the Top 7 Markets
11.1.1 Etopophos (Etoposide phosphate) - Bristol-Myers Squibb
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TESTICULAR NEOPLASM - PIPELINE DRUGS
12.1 List of Testicular Neoplasm Pipeline Drugs Across the Top 7 Markets
12.1.1 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Oxaliplatin - Dr Reddy's Laboratories/Pfizer/Sanofi/Yakult Honsha
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TESTICULAR NEOPLASM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TESTICULAR NEOPLASM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TESTICULAR NEOPLASM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Testicular Neoplasm - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Testicular Neoplasm - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Testicular Neoplasm - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Testicular Neoplasm - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Testicular Neoplasm - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Testicular Neoplasm - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Testicular Neoplasm - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Testicular Neoplasm - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Testicular Neoplasm - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Testicular Neoplasm - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Testicular Neoplasm - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Testicular Neoplasm - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Testicular Neoplasm - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Testicular Neoplasm - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Testicular Neoplasm - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Testicular Neoplasm - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Testicular Neoplasm - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Testicular Neoplasm - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Testicular Neoplasm - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Testicular Neoplasm - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Testicular Neoplasm - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Testicular Neoplasm - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Testicular Neoplasm - Access and Reimbursement Overview
16 TESTICULAR NEOPLASM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TESTICULAR NEOPLASM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TESTICULAR NEOPLASM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
